"Parathyroid Hormone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
| Descriptor ID |
D010281
|
| MeSH Number(s) |
D06.472.699.590 D12.644.548.587
|
| Concept/Terms |
Parathyroid Hormone- Parathyroid Hormone
- Hormone, Parathyroid
- PTH (1-84)
- Parathyroid Hormone (1-84)
- Parathormone
- Parathyrin
|
Below are MeSH descriptors whose meaning is more general than "Parathyroid Hormone".
Below are MeSH descriptors whose meaning is more specific than "Parathyroid Hormone".
This graph shows the total number of publications written about "Parathyroid Hormone" by people in this website by year, and whether "Parathyroid Hormone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 4 | 6 |
| 2008 | 0 | 7 | 7 |
| 2009 | 4 | 1 | 5 |
| 2010 | 1 | 4 | 5 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 3 | 7 | 10 |
| 2016 | 5 | 4 | 9 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 3 | 5 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 4 | 4 |
| 2022 | 2 | 4 | 6 |
| 2023 | 0 | 1 | 1 |
| 2024 | 4 | 2 | 6 |
| 2025 | 3 | 2 | 5 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parathyroid Hormone" by people in Profiles.
-
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial. J Bone Miner Res. 2026 Sep 24; 41(10):1069-1079.
-
Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial. J Bone Miner Res. 2026 Aug 21; 41(9):922-933.
-
Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. J Clin Endocrinol Metab. 2026 Mar 17; 111(4):945-952.
-
Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism. Eur J Endocrinol. 2025 Sep 30; 193(4):428-439.
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
-
Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
-
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):951-960.
-
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
-
Adolescent Hyperparathyroidism: An Updated Contemporary Surgical Experience at a Tertiary Center. J Surg Res. 2025 01; 305:150-155.
-
Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment Designation. Clin J Am Soc Nephrol. 2025 Feb 01; 20(2):218-228.